The Benefits of the Measureof Epicardial Adipose Tissue During Coronary Calcium Assessment of the Refine Cardiovascular Risk Assessment at Reunion Island.

The goal of this retrospective study is to see whether patients with familial partial type 2 lipodystrophy, who are at high cardiovascular risk present a higher volume of visceral epicardial adipose tissue than other patients without familial partial lipodystrophy who were assessed for their cardiovascular risk using coronary artery calcification scoring between 2016 and 2024.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

High Cholesterol Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diabetes Diabetes Mellitus Dyslipidemias Endocrine System Diseases Genetic Diseases, Inborn Glucose Metabolism Disorders Hypercholesterolemia Hyperlipidemias Laminopathies Lipid Metabolism Disorders Lipid Metabolism, Inborn Errors Lipodystrophy Lipodystrophy, Familial Partial Metabolic Diseases Nutritional and Metabolic Diseases Skin Diseases Skin Diseases, Metabolic Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de La Réunion

Saint-Pierre, Reunion

About this study

Coronary artery calcification and clinical cardiovascular risk scoring are insufficient for patients with Familial Partial Lipodystrophy Part 2 (FPLD2), who often develop cardiovascular events before 40 and are insulin resistant. Epicardial adipose tissue volume could be a new, earlier marker of interest for these patients related to inflammation and atherosclerosis. The investigators retrospectively included high cardiovascular risk patients from 2016 to 2023 who had benefited from coronary artery calcification and clinical risk scoring at the University Hospital of La Réunion with Familial Partial Lipodystrophy Type 2 or controls and paired them for age, sex and body mass index. Epicardial adipose tissue volume was measured on the same tododensitometry as the CAC scoring, using a semi, automated technique that had been validated with deep learning at the Univeristy Hospital of Aix-Marseille.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who received a check-up for hypercholesterolemia, obesity or diabetes including a CT scan to measure the coronary calcium score at the CHU de La Réunion between 2016 and 2023

Exclusion criteria

None

Treatment and study plan

Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring

Other

Epicardial adipose tissue measurement

Primary outcomes

Epicardial adipose tissue volume

Time frame: at inclusion

in mL

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de la Réunion

Other

Collaborators

Aix Marseille Université
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Institut National de la Santé Et de la Recherche Médicale, France

Registry information

Acronym: EPICAC-RUN

Important dates

Study start: 2024
Primary completion: 2024
Study completion: 2025
First posted: Jul 29, 2025
Registry last updated: Jul 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed